Content area

|
|

Ny viden om prognose for og behandling af børneabsenceepilepsi

Klassisk spike-wave-paroksysme.
Forfatter(e)
Joakim Bloch1 & Maria J. Miranda2 1) SUND, Københavns Universitet 2) Børneafdelingen, Herlev Hospital Ugeskr Læger 2017;179:V09160673
Reference: 
Ugeskr Læger 2017;179:V09160673
Blad nummer: 
Sidetal: 
2113-2117
Scientific evidence on treatment and prognosis of childhood absence epilepsy
Until now, ethosuximide (ESM), sodium valproate (VPA) and lamotrigine have been considered the drugs of choice in the management of childhood absence epilepsy, and there has been no high-validated evidence to distinguish their effects. New research shows, however, that while VPA and ESM are equally effective, ESM is the best tolerated of the two drugs, when considering cognitive adverse effects. This is of major importance, as cognitive comorbidities can be dire in childhood absence epilepsy, possibly affecting the psychosocial prognosis of the patients. More research is needed in this area.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Per E. Holstein | 17/12
7 kommentarer
af Elo Aagaard Rasmussen | 17/12
19 kommentarer
af Hanne Hermann | 17/12
1 Kommentar
af Mette Holland-Fischer | 17/12
1 Kommentar
af Erik Sloth | 17/12
8 kommentarer
af Frank Thor Jørgensen | 16/12
2 kommentarer
af Trine Cecilie Jeppesen | 15/12
1 Kommentar
af Lars Linnet | 14/12
1 Kommentar